RxDoctor Payments Data

Linus Ejim, MD

Nephrology · Sandersville, GANPI 1922091990

Payments from drug & device makers

$1,272in general payments, 2019–2025

Across 73 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$519
  • Vifor Pharma, Inc.$258
  • Bayer$241
  • Amgen$67
  • OPKO Pharmaceuticals, LLC$66
  • Ardelyx, Inc.$65
  • plus $56 from 2 others

What the payments were for

  • Food & beverage$1,19294%
  • Education$806%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)29$519
Vifor Pharma, Inc.16$258
Bayer12$241
Amgen(2 entities)3$67
OPKO Pharmaceuticals, LLC3$66
Ardelyx, Inc.3$65
Novartis1$29
Travere Therapeutics, Inc.6$27

How this compares

$1,272 in reported general payments places this provider in the 40th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$31,300
Medicare patients
75
Services billed
354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RayaldeeCalcifediol38$48,671
FarxigaDapagliflozin Propanediol46$33,760
OzempicSemaglutide21$31,382
JanuviaSitagliptin Phosphate16$18,338
EliquisApixaban28$15,410
Bydureon BciseExenatide Microspheres11$8,953
Calcitriol292$6,885
Alphagan PBrimonidine Tartrate11$3,781
Ventolin HfaAlbuterol Sulfate43$2,361
Pantoprazole Sodium130$1,940
Lactulose56$1,641
Sevelamer Carbonate13$1,490
Levetiracetam24$1,452
Divalproex Sodium ErDivalproex Sodium13$1,404
Amlodipine Besylate237$1,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
OPKO Pharmaceuticals, LLCRayaldee$66$48,67138 claims
AstraZenecaFarxiga$519$33,76046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 388 nephrology providers in Georgia.

Other nephrology in Sandersville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →